Heng Sheng Sow Selected Research

Vaccines

6/2018

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Heng Sheng Sow Research Topics

Disease

8	Neoplasms (Cancer) 01/2023 - 06/2018
3	Melanoma (Melanoma, Malignant) 01/2023 - 06/2018
2	Hypersensitivity (Allergy) 10/2020 - 01/2020
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2023
1	Triple Negative Breast Neoplasms 07/2022
1	Immediate Hypersensitivity 10/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Cytokine Release Syndrome 01/2020
1	Experimental Melanoma 06/2018
1	Bacterial Infections (Bacterial Infection) 01/2018

Drug/Important Bio-Agent (IBA)

3	AntigensIBA 01/2023 - 06/2018
3	Immunoglobulin E (IgE)IBA 01/2023 - 01/2020
3	Immunoglobulin G (IgG)IBA 01/2019 - 01/2018
2	chondroitin sulfate proteoglycan 4IBA 01/2023 - 01/2020
2	AntibodiesIBA 10/2020 - 06/2018
2	Monoclonal AntibodiesIBA 01/2020 - 01/2020
2	CytokinesIBA 01/2020 - 01/2019
1	Fc Receptors (Fc Receptor)IBA 01/2023
1	N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamideIBA 07/2022
1	Complement System Proteins (Complement)IBA 07/2022
1	Cyclin EIBA 07/2022
1	avelumabIBA 07/2022
1	Tryptases (Tryptase)IBA 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	Angiotensin IIIBA 01/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Interleukin-2 (IL2)IBA 12/2018
1	LigandsIBA 12/2018
1	VaccinesIBA 06/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018

Therapy/Procedure

5	Therapeutics 01/2023 - 06/2018
4	Immunotherapy 01/2023 - 01/2019